Clinical Trials Detalhe
A Study to Evaluate the Efficacy and Safety of CP-101,606 in Subjects With an Acute Stroke
Visão Geral
Gender
ALL
Idade
from 40 Years to 90 Years
Fase
PHASE2
Tipo de Estudo
INTERVENTIONAL
Localização
Pfizer Investigational Site (Coimbra, Portugal)
Pfizer Investigational Site (Lisbon, Portugal)
Clinicaltrial.gov
https://classic.clinicaltrials.gov/ct2/show/NCT00073476Sumário
The purpose of this study is to determine whether a new research medication is effective and safe for the treatment of acute stroke when given within 6 hours of the onset of stroke.
Condições
Stroke
Elegibilidade
Inclusion Criteria: Males \& females age 40-90 years Enrolled in study within 6 hours of onset of stroke symptoms Willing to sign informed consent form No significant disabilities prior to stroke Exclusion Criteria: Treatment with t-PA (tissue plasminogen activator) Premorbid modified rankin scale score of 2 or more